Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis

Completed · Phase 3 · Has a placebo group

Conditions studied: Tinea Pedis

In brief

This is a 6-week, double-blind, randomized, placebo-controlled, multicenter, parallel group Phase 3 study of NAFT-600 applied once a day for 2 weeks compared to vehicle (placebo) in the treatment of tinea pedis.

Key facts

Study ID

NCT01290341

Run by

Merz North America, Inc.

People needed

860

Starts

2011-02-01

Expected to finish

2011-12-01

Last updated by the study team

2013-09-26

Who can join

Age: 12 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males or non-pregnant females, ≥12 years of age, of any race or sex. Females of child-bearing potential must have a negative urine pregnancy test.
• For minors (less than 18 years), the parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).
• Presence of interdigital only or both interdigital and moccasin types of tinea pedis on one or both feet characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling and mild pruritus) based on signs and symptoms in the affected area(s).

You may not qualify if…

• Subjects with life-threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina or myocardial infarction) within the last 6 months.
• Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.
• Subjects with a known hypersensitivity to study drugs or their components.
• Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
• Uncontrolled diabetes mellitus.
• Hemodialysis or chronic ambulatory peritoneal dialysis therapy.
• Current diagnosis of immunocompromising conditions.
• Foot psoriasis, corns and/or callus involving any web spaces, atopic or contact dermatitis.
• Severe dermatophytoses, onychomycosis (on the evaluated foot), mucocutaneous candidiasis or bacterial skin infection.
• Extremely severe tinea pedis (incapacitating).
• Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study.

Where it is running

• Radiant Research, Inc. — Tucson, Arizona, United States
• T. Joseph Raoof, MD, Inc. — Encino, California, United States
• Walter K. Nahm, MD, PhD, Inc. — San Diego, California, United States
• Colorado Medical Research Center — Denver, Colorado, United States
• Longmont Clinic, PC — Longmont, Colorado, United States
• Tampa Bay Medical Research — Clearwater, Florida, United States
• Lake Washington Foot and Ankle Center — Melbourne, Florida, United States
• Clinical Research Atlanta — Stockbridge, Georgia, United States
• Hudson Dermatology — Evansville, Indiana, United States
• Department of Veterans Affairs — Minneapolis, Minnesota, United States
• Academic Dermatology Associates — Albuquerque, New Mexico, United States
• Radiant Research, Inc — Cincinnati, Ohio, United States
• Radiant Research, Inc. — Columbus, Ohio, United States
• Oregon Dermatology & Research Center — Portland, Oregon, United States
• Temple University- School of Podiatric Medicine — Philadelphia, Pennsylvania, United States
• Palmetto Clinical Trial Services, LLC — Simpsonville, South Carolina, United States
• DermResearch, Inc. — Austin, Texas, United States
• J&S Studies, Inc. — College Station, Texas, United States
• Research Across America — Dallas, Texas, United States
• Endeavor Clinical Trials, PA — San Antonio, Texas, United States
• Progressive Clinical Research — San Antonio, Texas, United States
• The Education and Research Foundation, Inc. — Lynchburg, Virginia, United States
• Madison Skin and Research, Inc — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.